Comparison of standardized uptake value of 18F-FDG-PET-CT with 21-gene recurrence score in estrogen receptor-positive, HER2-negative breast cancer

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer

(2015) Joseph A. Sparano et al.   NEW ENGLAND JOURNAL OF MEDICINE

[18F]-Fluorodeoxyglucose Positron Emission Tomography Can Contribute to Discriminate Patients with Poor Prognosis in Hormone Receptor-Positive Breast Cancer

(2014) Sung Gwe Ahn et al.   PLoS One

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

(2013) A. Goldhirsch et al.   ANNALS OF ONCOLOGY

A decision impact, decision conflict and economic assessment of routine Oncotype DX testing of 146 women with node-negative or pNImi, ER-positive breast cancer in the UK

(2013) S Holt et al.   BRITISH JOURNAL OF CANCER

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

(2013) Antonio C. Wolff et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic Significance of Progesterone Receptor–Positive Tumor Cells Within Immunohistochemically Defined Luminal A Breast Cancer

(2012) Aleix Prat et al.   JOURNAL OF CLINICAL ONCOLOGY

Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation

(2009) M. G. Vander Heiden et al.   SCIENCE

Expression of centromere protein F (CENP-F) associated with higher FDG uptake on PET/CT, detected by cDNA microarray, predicts high-risk patients with primary breast cancer

(2008) Shigeto Ueda et al.   BMC CANCER